Publications – Damona Pharmaceuticals TM

Thomas Prevot
March 25, 2022

New Research Article: Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits

New Research Article: Reduced inhibition in depression impairs stimulus processing in human cortical microcircuits https://www.damonapharma.com/wp-content/uploads/2022/03/1-s2.0-S2211124721017411-fx1.jpg 375 375 Thomas Prevot Thomas Prevot https://secure.gravatar.com/avatar/441964589afd9a17fb378ee0cd8d1fed?s=96&d=mm&r=g March 25, 2022 March 25, 2022

Through a multicentered collaboration, joining experts from the Centre for Addiction and Mental Health (CAMH) and University Health Network (UHN), Yao and colleagues are presenting this new release, highlighting how depression impairs cortical inhibition and stimulus processing Find Article Cortical processing depends on finely tuned excitatory and inhibitory connections in neuronal microcircuits. Reduced inhibition by…

Thomas Prevot
January 16, 2021

New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype

New Research Article shows Beneficial Effects of a New Drug in Transgenic Mouse Model with Cognitive Dysfunctions and Anxiety Phenotype https://www.damonapharma.com/wp-content/uploads/2021/01/Capture-wWebsite.jpg 613 472 Thomas Prevot Thomas Prevot https://secure.gravatar.com/avatar/441964589afd9a17fb378ee0cd8d1fed?s=96&d=mm&r=g January 16, 2021 January 16, 2021

The paper was published by Fee et al. in the International Journal of Neuropsychopharmacology. Patients suffering from mood and anxiety disorders often exhibit a deficit in brain inhibition. This deficit in brain inhibition is due do dysfunctional somatostatin (SST) cells, causing mood and cognitive symptoms in patients. Using transgenic mice in which the SST cell…

Thomas Prevot
November 5, 2020

A new molecule shows efficacy at reversing brain atrophy observed during aging

A new molecule shows efficacy at reversing brain atrophy observed during aging https://www.damonapharma.com/wp-content/uploads/2019/01/Lightspring_Brain_Medication.jpg 639 450 Thomas Prevot Thomas Prevot https://secure.gravatar.com/avatar/441964589afd9a17fb378ee0cd8d1fed?s=96&d=mm&r=g November 5, 2020 January 4, 2021

Drs. Prevot, Sibille and Colleagues just published their finding in the Journal Cerebral Cortex, about a new molecule reversing brain atrophy and memory dysfunction observed during aging. During aging, our brain tends to slowly shrink in size due to neuronal shrinkage and reduced function. This phenomenon participates in the emergence of cognitive and memory deficits,…

Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders

Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders https://www.damonapharma.com/wp-content/uploads/2020/04/article-image4.png 1920 800 Etienne Sibille Etienne Sibille https://secure.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=g April 28, 2020 June 4, 2020

Cognitive dysfunctions, including impaired attention, learning, memory, planning and problem solving, occur in depressive episodes, often persist during remission, predict relapse, worsen with recurrent episodes, and are not treated by current antidepressants or other medications.

https://rdcu.be/b3PSq

Insight into Novel Treatment for Cognitive Dysfunctions across Disorders

Insight into Novel Treatment for Cognitive Dysfunctions across Disorders https://www.damonapharma.com/wp-content/uploads/2020/04/article-image6.png 1920 800 Etienne Sibille Etienne Sibille https://secure.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=g March 28, 2019 June 4, 2020

Cognitive dysfunctions, including impaired attention, learning, memory, and problem solving, occur in psychiatric diseases, such as depression, and are a hallmark of aging.

https://pubs.acs.org/doi/full/10.1021/acschemneuro.9b00148

Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles

Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles https://www.damonapharma.com/wp-content/uploads/2019/03/article-novel-benbanner.jpg 1920 1000 Etienne Sibille Etienne Sibille https://secure.gravatar.com/avatar/31fca8d52a9ddc2456d689e55abc91df?s=96&d=mm&r=g January 23, 2019 June 1, 2020

Altered gamma-aminobutyric acid (GABA) function is consistently reported in psychiatric disorders, normal aging, and neurodegenerative disorders and reduced function of GABA interneurons is associated with both mood and cognitive symptoms.

https://www.karger.com/Article/Fulltext/496086